Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes—2022

Diabetes Care (2021) Vol. 45, Iss. Supplement_1, pp. S175-S184
Closed Access | Times Cited: 138

Showing 1-25 of 138 citing articles:

Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
Colin Baigent, Jonathan Emberson, Richard Haynes, et al.
The Lancet (2022) Vol. 400, Iss. 10365, pp. 1788-1801
Open Access | Times Cited: 611
Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)
Ian H. de Boer, Kamlesh Khunti, Tami Sadusky, et al.
Diabetes Care (2022) Vol. 45, Iss. 12, pp. 3075-3090
Open Access | Times Cited: 417
An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
Teresa Salvatore, Raffaele Galiero, Alfredo Caturano, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 7, pp. 3651-3651
Open Access | Times Cited: 149
Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE)
Jennifer B. Green, Amy K. Mottl, George L. Bakris, et al.
Nephrology Dialysis Transplantation (2022) Vol. 38, Iss. 4, pp. 894-903
Open Access | Times Cited: 108
Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus
David B. Sacks, Mark A. Arnold, George L. Bakris, et al.
Diabetes Care (2023) Vol. 46, Iss. 10, pp. e151-e199
Open Access | Times Cited: 88
Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease
Yaofu Zhang, Li Jiang, Junheng Wang, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 50
Patient Management and Clinical Outcomes Associated with a Recorded Diagnosis of Stage 3 Chronic Kidney Disease: The REVEAL-CKD Study
Navdeep Tangri, Emily Peach, Stefan Franzén, et al.
Advances in Therapy (2023) Vol. 40, Iss. 6, pp. 2869-2885
Open Access | Times Cited: 24
The Pivotal Role of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Hypertension Management and Cardiovascular and Renal Protection: A Critical Appraisal and Comparison of International Guidelines
Luis Alcocer, Alfonso Bryce, David Brasil, et al.
American Journal of Cardiovascular Drugs (2023) Vol. 23, Iss. 6, pp. 663-682
Open Access | Times Cited: 24
Novel Therapeutic Agents for Management of Diabetes Mellitus: A Hope for Drug Designing against Diabetes Mellitus
Ahmed M. E. Elkhalifa, Mehak Nazar, Sofi Imtiyaz Ali, et al.
Life (2024) Vol. 14, Iss. 1, pp. 99-99
Open Access | Times Cited: 14
Use of SGLT2 Inhibitors vs GLP-1 RAs and Anemia in Patients With Diabetes and CKD
Jia-Chian Hu, Shih‐Chieh Shao, Daniel Hsiang-Te Tsai, et al.
JAMA Network Open (2024) Vol. 7, Iss. 3, pp. e240946-e240946
Open Access | Times Cited: 13
Measuring Albuminuria in Individuals With Obesity: Pitfalls of the Urinary Albumin-Creatinine Ratio
Avry Chagnac, Allon N. Friedman
Kidney Medicine (2024) Vol. 6, Iss. 4, pp. 100804-100804
Open Access | Times Cited: 10
Recent Updates to Clinical Practice Guidelines for Diabetes Mellitus
Jin Yu, Seung‐Hwan Lee, Mee Kyoung Kim
Endocrinology and Metabolism (2022) Vol. 37, Iss. 1, pp. 26-37
Open Access | Times Cited: 38
Prognostic Nutritional Index as a Predictor of Diabetic Nephropathy Progression
Junlin Zhang, Xiang Xiao, Yucheng Wu, et al.
Nutrients (2022) Vol. 14, Iss. 17, pp. 3634-3634
Open Access | Times Cited: 37
Overcoming barriers to implementing new guideline-directed therapies for chronic kidney disease
Robert Nee, Christina M. Yuan, Andrew S. Narva, et al.
Nephrology Dialysis Transplantation (2022) Vol. 38, Iss. 3, pp. 532-541
Open Access | Times Cited: 32
Influence of SGLT2i and RAASi and Their Combination on Risk of Hyperkalemia in DKD
Xiaoling Luo, Jing Xu, Shoulian Zhou, et al.
Clinical Journal of the American Society of Nephrology (2023) Vol. 18, Iss. 8, pp. 1019-1030
Closed Access | Times Cited: 19
Dose-response association of diabetic kidney disease with routine clinical parameters in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
Jianbo Guo, Chen Liu, Yifan Wang, et al.
EClinicalMedicine (2024) Vol. 69, pp. 102482-102482
Open Access | Times Cited: 8
Emerging role of antidiabetic drugs in cardiorenal protection
Wen-Jia Fu, Jin-Ling Huo, Zi‐Hui Mao, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 7
Prescription Patterns of Cardiovascular- and Kidney-Protective Therapies Among Patients With Type 2 Diabetes and Chronic Kidney Disease
Julio A. Lamprea‐Montealegre, Erin Madden, Sri Lekha Tummalapalli, et al.
Diabetes Care (2022) Vol. 45, Iss. 12, pp. 2900-2906
Open Access | Times Cited: 27
Integrating CKD Into US Primary Care: Bridging the Knowledge and Implementation Gaps
Joseph A. Vassalotti, Suelyn C. Boucree
Kidney International Reports (2022) Vol. 7, Iss. 3, pp. 389-396
Open Access | Times Cited: 23
The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice
Bernt Johan von Scholten, Frederik Flindt Kreiner, Søren Rasmussen, et al.
Therapeutic Advances in Endocrinology and Metabolism (2022) Vol. 13
Open Access | Times Cited: 23
Synergistic effect of chronic kidney disease, neuropathy, and retinopathy on all-cause mortality in type 1 and type 2 diabetes: a 21-year longitudinal study
Luca Sacchetta, Martina Chiriacò, Lorenzo Nesti, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 23
Evolution of sodium-glucose co-transporter 2 inhibitors from a glucose-lowering drug to a pivotal therapeutic agent for cardio-renal-metabolic syndrome
Hiroki Akiyama, Akihiro Nishimura, Naru Morita, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 16
Machine Learning for Predicting Micro- and Macrovascular Complications in Individuals With Prediabetes or Diabetes: Retrospective Cohort Study
Simon Schallmoser, Thomas Zueger, Mathias Kraus, et al.
Journal of Medical Internet Research (2023) Vol. 25, pp. e42181-e42181
Open Access | Times Cited: 16
Impact of individual microvascular disease on the risks of macrovascular complications in type 2 diabetes: a nationwide population-based cohort study
Fu‐Shun Yen, James Cheng‐Chung Wei, Ying‐Hsiu Shih, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 16
Gender Differences in the Incidence of Nephropathy and Changes in Renal Function in Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Study
Fan Zhang, Yan Han, Guojun Zheng, et al.
Diabetes Metabolic Syndrome and Obesity (2024) Vol. Volume 17, pp. 943-957
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top